Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire August 3, 2017

Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow

PR Newswire July 27, 2017

Watch These 7 Huge Call Purchases In Monday Trade

Benzinga.com  July 3, 2017

GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting

PR Newswire June 21, 2017

Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant

PR Newswire June 21, 2017

Agenus to Webcast Annual Meeting of Stockholders

PR Newswire June 21, 2017

Agenus' anti-CTLA-4 antibody shows strong safety and tolerability

PR Newswire June 5, 2017

Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences

PR Newswire June 1, 2017

Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting

PR Newswire May 22, 2017

Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma

PR Newswire May 19, 2017

Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire May 4, 2017

Investor Network: Agenus Inc. to Host Earnings Call

Accesswire May 4, 2017

Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow

PR Newswire April 27, 2017

Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins

PR Newswire April 20, 2017

Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™

PR Newswire April 5, 2017

Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies

PR Newswire March 30, 2017

Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia

PR Newswire March 30, 2017

Agenus to Participate at Two Upcoming Immuno-Oncology Conferences

PR Newswire March 24, 2017

Agenus Reports Fourth Quarter and Full Year 2016 Results

PR Newswire March 9, 2017

Four Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting

PR Newswire March 7, 2017